Welcome to our dedicated page for Reliance Global Group news (Ticker: EZRA), a resource for investors and traders seeking the latest updates and insights on Reliance Global Group stock.
Reliance Global Group reports news about its insurance and InsurTech operating foundation, financial results and strategic venture investments. Recurring company updates cover the RELI Exchange platform for independent insurance agencies, agency recruiting and productivity initiatives, and business updates tied to the company's insurance commission-based operations.
News also covers EZRA International Group and Reliance's ownership-driven investments in technology and life sciences. Recent themes include Enquantum's post-quantum cryptography platform, LifeSci Global's healthcare investment mandate, Innervate Radiopharmaceuticals' radiopharmaceutical development work, conference participation and governance or capital-allocation updates tied to the company's strategic ventures model.
Reliance Global Group (Nasdaq: EZRA) closed its strategic acquisition of Enquantum Ltd. on Feb 23, 2026, starting a milestone-driven path toward a 51% fully diluted controlling interest.
Enquantum develops hardware-accelerated, NIST-aligned post-quantum encryption for terabit-scale environments and holds a 2025 patent for FPGA-based quantum-resistant communications.
Reliance Global Group (Nasdaq: EZRA) signed a definitive agreement to acquire a 51% controlling interest in post-quantum cybersecurity company Enquantum, with an aggregate purchase price of $2,125,000 payable over ~10 months via milestone-tied tranches.
The deal implies a $2,041,667 pre-money valuation and $9.8018 per-share purchase price; initial close yields an 8% fully diluted stake (including conversion of a $166,000 bridge note). Closing expected within 30 days and remains subject to customary conditions.
Reliance Global Group (Nasdaq: EZRA) launched Scale51, an operating and acquisition model within new subsidiary EZRA International Group to acquire controlling 51% stakes in technology companies and scale them in the U.S.
Target sectors include AI/data analytics, cybersecurity, FinTech/InsurTech, and MedTech; potential early transactions with Enquantum and Scentech remain subject to diligence and definitive agreements.
Reliance Global Group (Nasdaq: EZRA) reported a 36% year-over-year increase in Personal Lines Property & Casualty written premium generated through RELI Exchange, rising from approximately $11.47 million in 2024 to approximately $15.6 million in 2025. Growth is attributed to an expanded agency partner network.
Since acquiring RELI Exchange in 2022, the company says its network grew from ~65 to ~300 agency partners, with expansion described as organic rather than acquisition-driven. The written premium figures are internal, unaudited, and presented as an operating metric not equivalent to GAAP revenue.
Reliance Global Group (Nasdaq: EZRA) reported a 72% increase in health insurance policies written through its RELI Exchange during the 2025 open enrollment period. Policies rose to approximately 3,873 in 2025 from 2,258 in 2024.
The company also expanded its broker network from approximately 65 agency partners at acquisition in 2022 to approximately 300 partners, and said RELI Exchange cash flow supports its EZRA International Group acquisition strategy.
Reliance Global Group (Nasdaq: EZRA) reported a 72% year-over-year increase in health insurance policies written through RELI Exchange during the 2025 open enrollment period, rising to approximately 3,873 policies from 2,258 in 2024. The company attributes growth to deeper carrier relationships and improved execution.
Since acquiring RELI Exchange in 2022, the broker network expanded from ~65 to ~300 agency partners, supporting higher policy volumes and helping fund the company’s broader strategic initiatives under EZRA International Group, including planned controlling investments in diagnostic and post-quantum cybersecurity firms.
Reliance Global Group (Nasdaq: EZRA) closed a public offering on January 29, 2026, raising approximately $2.0 million in gross proceeds.
The offering sold 7,407,408 common shares (or pre-funded warrants) and warrants to buy 14,814,816 shares at a combined public price of $0.27 per share.
The warrants are exercisable upon issuance, expire in two years, and H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended for working capital, M&A strategies and general corporate purposes.
Reliance Global Group (Nasdaq: EZRA) priced a public offering of 7,407,408 common shares (or pre-funded warrants) plus warrants to purchase up to 14,814,816 shares at a combined public offering price of $0.27 per unit.
The warrants are exercisable upon issuance at $0.27, expire in two years, and closing is expected on or about January 29, 2026. Gross proceeds are expected to be approximately $2.0 million; net proceeds are for working capital, M&A strategies and general corporate purposes. H.C. Wainwright is the exclusive placement agent; the Form S-1 was declared effective by the SEC on January 28, 2026.
Reliance Global Group (Nasdaq: EZRA) promoted Moshe Fishman to Senior Vice President, Strategic Ventures to lead its EZRA Group International platform while continuing to support the core insurance business.
Fishman will source and execute majority or controlling acquisitions, scale post-close integration, and advance recent transactions including announced majority stakes in Scentech Medical and Enquantum Ltd.
Reliance Global Group (Nasdaq: EZRA) entered a non-binding term sheet on Jan 26, 2026 to acquire a controlling stake in Enquantum, a post-quantum cryptography hardware company. Reliance advanced funding via a secured promissory note on Jan 15, 2026 that is secured by all Enquantum assets and payable within 60 days if no definitive agreement is reached, with amounts applied to early payment milestones if a deal closes. Enquantum holds a 2025 patent for FPGA-based quantum-resistant encrypted communications and is developing NIST-compliant, hardware-accelerated PQC targeting terabit Ethernet speeds. The transaction remains conditional on due diligence and definitive agreements.